

1 **Baseline Clinical, Hormonal and Molecular Markers Associated with Clinical Response to IL-23**  
2 **Antagonism in Hidradenitis Suppurativa: A Prospective Cohort Study**

3  
4  
5 A Flora MD<sup>1,2,3</sup>, EK Kozera MD MPH MBeth<sup>1,2</sup>, R Jepsen RN<sup>4</sup>, K Gill MD Candidate<sup>3</sup>, J Xu MD  
6 Candidate<sup>3</sup>, JW Frew MBBS(Hons) MMed MS PhD<sup>1,2,3,4</sup>

7  
8 <sup>1</sup>Department of Dermatology, Liverpool Hospital, Sydney Australia

9 <sup>2</sup>Laboratory of Translational Cutaneous Medicine, Ingham Institute, Sydney, Australia

10 <sup>3</sup>University of New South Wales, Sydney, Australia

11 <sup>4</sup>Holdsworth House Medical Practice, Sydney, Australia

12  
13  
14 Word Count: 2497

15 Figure Count: 5

16 Supp Fig Count: 8

17 Supp Table Count: 6

18  
19 **Corresponding Author**

20 Dr John W. Frew  
21 Laboratory of Translational Cutaneous Medicine,  
22 Department of Dermatology, Liverpool Hospital  
23 Suite 7, Level 1, 45-47 Goulburn St,  
24 Liverpool NSW 2170  
25 Ph: +61 2 87384560  
26 Fax: +61 2 87384639  
27 Email: [john.frew@unsw.edu.au](mailto:john.frew@unsw.edu.au)

28  
29  
30 **Keywords:** Hidradenitis Suppurativa, Interleukin-23, Hormones, Testosterone, Monocytes,  
31 Inflammation,

32  
33 **Funding:** Nil

34  
35 **Disclosure/ Conflict of Interest Statement:**

36 JWF has conducted advisory work for Janssen, Boehringer-Ingelheim, Pfizer, Kyowa Kirin, LEO  
37 Pharma, Regeneron, Chemocentryx, Abbvie, Azora, Novartis and UCB, participated in trials for  
38 Pfizer, UCB, Boehringer-Ingelheim, Eli Lilly, CSL, Azora and received research support from  
39 Ortho Dermatologics, Sun Pharma, LEO Pharma, UCB and La Roche Posay.  
40 AF, EK, RJ, KG, JX report no disclosures or conflicts of interest.

41  
42  
43 **Data Availability:** All gene expression data is available under GEO Accession *GSE214820*

44

45

46 **Ethics Approval Statement:**

47 This study was approved by the Human Research Ethics Committee of South Western Sydney

48 Local Health District.

49

50

51 **Contributor Statement:**

52 AF: Investigation, Methodology, Writing, Revision

53 EKK: Methodology, Writing, Revision

54 RJ: Investigation, Methodology, Writing, Revision

55 JX: Methodology, Writing, Revision

56 KG: Methodology, Writing, Revision

57 JWF: Conception, Funding, Supervision, Investigation, Methodology, Writing, Revision

58

59 **Data Availability Statement:**

60 The datasets used in this manuscript are publicly available through Gene Expression Omnibus

61 (GEO) via accession number GSE214820

62

63

64

65

66

67

68

69

70

71 **ABSTRACT**

72 **Background:** Hidradenitis Suppurativa is a complex inflammatory disease in which predicting  
73 therapeutic response remains challenging. IL-23 interacts with sex hormones but the  
74 relationships between the two in HS remains uninvestigated.

75 **Objectives:** To assess whether baseline clinical, hormonal, or molecular markers are associated  
76 with clinical response to IL-23 antagonism with Risankizumab in Hidradenitis Suppurativa.

77 **Methods:** 26 individuals with Hurley Stage 2/3 disease were administered Risankizumab 150mg  
78 Week 0,4,12. Baseline sex hormones and skin biopsies were taken. Clinical response at Week 16  
79 assessed by the HiSCR, and differences between responders and non-responders assessed.

80 **Results:** 18 of 26 participants achieved HiSCR50 at week 16 (69.2%). Clinical response to IL-23  
81 antagonism was associated with male gender, elevated total serum testosterone, and  
82 decreased levels of FSH. Stratification by clinical responders/non responders identified  
83 differentially expressed genes including *PLPP4* and *MAPK10*. Immunohistochemistry identified  
84 elevated numbers of CD11c, IL-17A and IL-17F positive cells compared to non-responders.  
85 CD11c+ cells significantly correlated with serum levels of total testosterone and inversely  
86 correlated with serum FSH.

87 **Conclusions:** Clinical response to IL-23 antagonism in HS is associated with serum sex  
88 hormones, Th17 polarized inflammation in lesional tissue and CD11c+ cells. These potential  
89 therapeutic biomarkers require further validation in larger cohorts but may suggest potential  
90 targeted HS therapy.

91

92 **Keywords:** Hidradenitis Suppurativa, Interleukin-23, Hormones, Testosterone, Monocytes,  
93 Inflammation,

94 **Main Text:**

95  
96  
97 Hidradenitis Suppurativa (HS) is a complex, heterogeneous inflammatory disease in need of  
98 novel therapies<sup>1</sup>. Currently, Adalimumab is the sole licensed biologic therapy for HS, and only  
99 achieves clinical response (as measured by the Hidradenitis Suppurativa Clinical Response  
100 outcome measure) in 60% of patients<sup>2</sup>. Mechanistically, HS is associated with significant  
101 polarization of the Th17 immune axis with significant dysregulation of cytokines including IL-  
102 17A<sup>3</sup>, IL-17C<sup>4</sup>, IL-17F<sup>3,5</sup> and IL-23<sup>3</sup>. Agents targeting the Th17 immune axis have been explored in  
103 HS<sup>6</sup> including clinical trials<sup>7</sup>, but further development has been halted due to lack of positive  
104 results<sup>8</sup>. Two separate IL-23 antagonists (Risankizumab and Guselkumab) have been withdrawn  
105 from further development after a lack of positive results in Phase 2 studies<sup>8</sup>, with no significant  
106 difference in clinical response when compared to placebo<sup>8</sup>(Supplementary Table 4). Isolated  
107 case reports and case series however, report benefit in some patients<sup>6,9</sup>

108  
109 HS also has a significant hormonal component to disease pathogenesis<sup>10</sup>. The link between sex  
110 hormones and the Th17 immunological axis is incompletely understood<sup>11</sup>. Perimenstrual  
111 disease flares, remission during pregnancy and the effect of comorbidities such as obesity and  
112 insulin resistance on hormone levels suggest sex hormones play an important role in  
113 modulating inflammation in HS<sup>12</sup>. Hormonal therapies such as Spironolactone, oral  
114 contraceptives and 5- $\alpha$  reductase inhibitors such as finasteride and dutasteride are used,  
115 primarily in female patients, with variable levels of efficacy<sup>12,13</sup>.

116

117 The Th17 immune axis is known to interact with sex hormones through IL-23<sup>14,15</sup>. IL-23 interacts  
118 with non-canonical androgen receptor signaling pathways, modulating inflammation in  
119 epithelial tissues and monocytes/macrophages<sup>14,15</sup>. Monocyte activation and development into  
120 macrophages are altered in the presence of tissue estrogens, (specifically E2 Estradiol) both in  
121 in vivo and in vitro investigations<sup>14,15</sup>. Monocytes and macrophages are known to be central  
122 players in the pathogenesis of HS<sup>16-19</sup>, produce IL-23, and are proposed to interact with T cells, B  
123 cells and Neutrophils to direct and orchestrate chronic inflammation in HS<sup>16-19</sup>.

124  
125 Recent Phase 2 studies of IL-23 antagonism in HS have suggested disparate clinical responses  
126 based upon participant gender, with primarily male cohorts demonstrating higher rates of  
127 clinical response to IL-23 antagonism compared to primarily female cohorts<sup>8</sup>. This would be  
128 consistent with sex hormones influencing the role of IL-23 directed inflammation in HS,  
129 however clinical and mechanistic evidence to support this hypothesis is currently lacking.

130  
131 The aim of this prospective cohort study was to assess whether baseline clinical, hormonal or  
132 molecular markers are associated with clinical response to IL-23 antagonism with Risankizumab  
133 in Hidradenitis Suppurativa.

134  
135 **METHODS:**

136  
137 26 individuals with dermatologist diagnosed HS (based upon the modified Dessau criteria<sup>20</sup>)  
138 were included in this cohort study. All individuals had Hurley stage 2 or 3 disease and a  
139 minimum of 5 inflammatory lesions (abscesses and nodules). Inclusion and Exclusion criteria  
140 are presented in supplementary table 1. Clinical data including demographics, smoking status,

141 body mass index (BMI), family history of HS, and diagnosed insulin resistance were collated  
142 (Supplementary Table 2). Disease severity was assessed using Hurley staging and lesion counts  
143 using the international hidradenitis suppurativa severity score (IHS4) outcome measure<sup>2</sup>.  
144 Baseline blood work including serum total and free testosterone, follicular stimulating hormone  
145 (FSH), luteinizing hormone (LH), sex hormone binding globulin (SHBG) as well as C reactive  
146 protein (CRP) levels. All participants were administered Risankizumab at psoriasis dosing of  
147 150mg week 0,4 and 12. The primary outcomes of interest was clinical response as measured  
148 by the Hidradenitis Suppurativa Clinical Response (HiSCR<sup>2</sup>) at week 16. Additional outcomes  
149 included the IHS4, as well as HiSCR75 (defined as a 75% reduction in Abscess and Nodule count  
150 without an increase in abscesses or draining tunnels), and HiSCR90 (defined as a 90% reduction  
151 in Abscess and Nodule count without an increase in abscesses or draining tunnels) as used in  
152 the recent Bimekizumab Phase 2 clinical trial in HS<sup>21</sup>. Clinical Responders were defined as  
153 individuals who achieved HiSCR at Week 16. Non-Responders were defined as those who did  
154 not achieve HiSCR 50 at Week 16.

155

156

157 *Skin Biopsy Collection and Processing:*

158 Lesional, peri-lesional and non-lesional skin biopsies were taken prior to the commencement of  
159 Risankizumab using previously described standardized lesion and site methodologies<sup>22</sup>. Each  
160 6mm biopsy specimen was bisected, with one section immediately placed in RNA later and  
161 frozen at -80 degrees Celsius until processing for RNA extraction. The other section was placed  
162 in OCT medium and frozen at -80 degrees Celsius and processed for Immunohistochemistry.

163

164 RNA was extracted using the Qiagen RNEasy kit then eluted in 50ug of RNA-ase free water. RNA  
165 was processed and analysed using the Nanostring nCounter Fibrosis 2.0 multiplex gene  
166 expression assay (gene list in Supplementary Table 3). nCounter technology uses a pair of gene-  
167 specific probes – a capture probe and a reporter probe – with each aligning to their target RNA  
168 by complementary base pairing. The reporter probe contains a target-specific fluorophore, and  
169 readout is via an imaging platform that identifies and quantifies probe complexes<sup>23</sup>.

170  
171 Tissue sections in OCT were cut into 5.0µm sections and stained for the following proteins of  
172 interest: IL-17A (Thermofisher 14717982, 1:100), IL-17F (Thermofisher PA5115403 1:100), IL-  
173 23p19 (Thermofisher PA520239 1:100) and Cd11c (Proteintech KHC0017) Appropriate  
174 secondary antibodies (Abcam goat anti-mouse Ab6789 1:2000), Abcam goat anti rabbit Ab6721  
175 1:200) were used with DAB chromophore. IHC quantification was undertaken using  
176 semiquantitative measurement by 2 experienced independent raters (AF, JWF), with any  
177 disagreement mediated by a third author.

178  
179 *Statistical Analysis:*

180 Power calculation was undertaken to determine the significance of findings. Assuming a clinical  
181 response rate of 40% similar to clinical trial data<sup>8</sup>, a sample size of 26 participants will allow  
182 detection of significant change in two markers (with log fold change greater than 1.5) with  
183 power greater than 80% if one tailed significance T-tests is performed.

184

185 Descriptive statistics were used to collate all demographic and disease severity data in the  
186 included patients. Differences between groups (Responders/Non responders) were analyzed  
187 using Chi Squared analysis for binary/dichotomous variables and the Wilcoxon Rank sum test  
188 for continuous variables.  $P < 0.05$  was considered statistically significant and adjustment for  
189 multiple comparisons was made using the Benjamini Hochberg procedure. All statistical analysis  
190 was completed in Graphpad Prism (9.4.1)

191  
192 *Analysis of Serum Sex Hormones:*

193 Serum sex hormones were measured by the same laboratory across all individuals. All pre-  
194 menopausal female participants underwent baseline blood tests during the first 3 days of their  
195 menstrual cycle to account for cyclical variation. As per the exclusion criteria- no women in this  
196 cohort study were on active hormonal contraception. Differences between groups were  
197 analyzed using Wilcoxon Rank sum test for continuous variables.  $P < 0.05$  was considered  
198 statistically significant and adjustment for multiple comparisons was made using the Benjamini-  
199 Hochberg procedure.

200  
201  
202 *Immunohistochemistry quantification:*

203 IHC staining underwent semiquantitative analysis using previously published methods<sup>24</sup>.  
204 Differences between groups were analyzed using the Wilcoxon rank sum test with adjustment  
205 for multiple comparisons was made using the Benjamini Hochberg procedure.

206  
207 *Nanostring NCounter Analysis:*



208 Extracted RNA was analysed using the NCounter system (Nanostring) using the Human Fibrosis  
209 V2.0 gene panel. Raw data was processed using the Nanostring Nsolver (version 4.0.70) analysis  
210 software using quality control and normalization procedures derived from the NormqPCR R  
211 package as previously described<sup>25</sup>. Differentially expressed genes (DEGs) were defined as >1.5  
212 Log2Fold change with a false discovery rate<0.05 and p value<0.05.

213  
214  
215  
216  
217

## RESULTS:

218 Clinical response to IL-23 antagonism was significantly associated with male gender, insulin  
219 resistance and serum sex hormones

220 Eighteen of the twenty-six included participants were classified as responders (69.2%), having  
221 achieved HISCR at Week 16. Responders demonstrated dramatic reduction in the number of  
222 clinically apparent nodules and abscesses, but also draining tunnels as well as diffuse erythema,  
223 pain and swelling (Supplementary Figure 1). The demographic and disease characteristics of the  
224 included patients (including Responders and Non-Responders) is presented in Table 1. A  
225 statistically significant difference in the proportion of male participants in the responder  
226 category when compared to the non-responder category as measured by the Chi Squared test.  
227 (77.8% vs 12.5% p<0.01). There was no significant difference between responders and non-  
228 responders with regards to age, BMI, or Hurley stage (Table 1). Significant differences in total  
229 testosterone, FSH and LH were also identified between responders and non-responders. (Table  
230 1, Figure 2).

231

232 The univariate association of clinical response as measured by HiSCR (hereafter termed  
233 HiSCR50) was maintained when deeper measures of clinical response (HiSCR75 and HiSCR90)  
234 were analyzed (Supp Figures). Statistically significant differences between serum FSH and  
235 serum total testosterone were identified between HiSCR75 Responders/ Non-Responders. Only  
236 serum total testosterone was statistically significant between HiSCR90 Responders/Non-  
237 Responders/ (Supplementary Figures 2,3,4,5).

238 No statistically significant differences between HiSCR Responders/ Non-Responders were seen  
239 between other hormonal measurements including sex hormone binding globulin (SHBG), free  
240 testosterone and serum luteinizing hormone (LH). (Supplementary Figures 2,3,4,5) Additionally,  
241 exploratory correlation between age and BMI did not reveal any statistically significant  
242 difference between clinical Responders and Non-Responders (Supplementary Figures 2,3,4,5).

243 Examination of deeper levels of response including HiSCR75 and HiSCR90 also did not identify  
244 any significant differences between responders and non-responders. (Supplementary Figures  
245 2,3,4,5)

246

247 Analysis of the relationship between clinical response and FSH/total testosterone by multiple  
248 regression analysis did not reveal any loss of association in the presence of other identified  
249 variables (Supplementary Table 6). This indicates that serum total testosterone and serum FSH  
250 are consistently associated with clinical response, as measured by HiSCR50/75/90 outcome  
251 measures, even in the presence of other demographic and hormonal variables.

252  
253  
254

255 HS Lesional, Perilesional and Non-Lesional Tissue Demonstrates Dysregulation of Multiple  
256 Inflammatory and Immunological Pathways by Multiplex Gene Expression, similar to those  
257 observed in whole tissue RNA sequencing  
258  
259  
260 Gene expression using multiplex gene expression (Nanostring nCounter Fibrosis 2.0 gene  
261 expression panel) identified significant dysregulation of fibro-inflammatory genes including  
262 *IL1B, CXCL8, SYK, CXCR1*) across lesional, perilesional and non lesional tissue (Figure 3). The  
263 highest differentially expressed genes (Supplementary Figure 6, 7) included genes and  
264 pathways previously identified in RNA sequencing including interferon responsive elements  
265 (*IRF1*), neutrophil activation (*CEACAM3*), B cell activity (*BLK*) and Th17 pathways (*IL17A*).  
266 Additionally, a number of novel genes and pathways were highlighted including CD8 cell  
267 exhaustion (*LAG3*), mast cell activity (*C4BPA*) and sex-hormone regulated monocyte associated  
268 genes (*PRAP1*).  
269 Principal component analysis (Supplementary Figure 6) identified specific genes significantly  
270 associated with lesional tissue (including *BLK, CD44, IL6, STAT3*), peri-lesional tissue (*IL10, C5,*  
271 *IRF1*) and non-lesional tissue (*ILK, COLA12, IL17A*). These genes and associated cell types have  
272 been observed in whole tissue RNAseq<sup>26,27,28</sup> validating the novel use of this technology in HS  
273 tissue.  
274  
275  
276 Molecular response stratified by HiSCR Responders/ Non-Responders identify upregulated T cell,  
277 Th17 associated genes and pathways in clinical responders to IL-23 antagonism  
278  
279 Stratification of baseline tissue gene expression by HiSCR50 responders and non-responders  
280 identified a number of genes associated with clinical response to Risankizumab therapy (Figure

281 4). The most differentially expressed genes pertained to extra cellular matrix synthesis (*MFAP3*,  
282 *CYP8B1*) as well as T cells (*TRAT1*), PPAR signaling (*CYP8B1*), mast cells (*TPSAB1/B2*) and  
283 cytokine signaling (*CXCR1*, *LTA*, *FADD*, *OAS1*). Statistically significant dysregulated genes are  
284 listed in Figure 4). Sex-hormone modulated genes including *PLPP4* and *MAPK10* were  
285 upregulated in responders compared to non-responders. Principal component analysis  
286 identified significant clustering between responders and non-responders when stratified by  
287 HiSCR50 (Figure 4). Pathway analysis by reactome identified interleukin-17 signaling,  
288 chemokine receptors, and signaling by interleukins, Innate immune system and immune system  
289 as significant pathways in responders versus non-responders (Supplementary Table 5).

290  
291  
292 *Immunohistochemistry identifies Th17 associated proteins such as IL-17A, IL-17F and IL-23p19*  
293 *as well as and CD11c+ leucocytes as associated with clinical response in HS lesional tissue.*

294  
295 Confirmatory IHC indicates significantly increased number of CD11c+ cells and IL23p19+ cells in  
296 dermal infiltrates in lesional tissue of clinical responders (as measured by HiSCR) when  
297 compared to clinical non-responders. (Supplementary Figure 8). Semiquantitative cell counts  
298 identified elevated levels of IL-17A and IL-17F positive cells in dermal infiltrates of lesional  
299 tissue in clinical responders (Figure 5). Univariate correlation identified a significant association  
300 between Serum FSH and Serum testosterone with semiquantitative IHC cell counts of CD11c  
301 and IL23p19 positive cells (Supplementary Figure 8).

302  
303  
304  
305

306

307 **Discussion:**

308 Clinical response to IL-23 antagonism with Risankizumab in HS is associated with baseline  
309 elevation in total testosterone and baseline suppression of FSH, as well as upregulation of sex-  
310 hormone responsive genes including *PLPP4* and *MAPK10* in lesional tissue. The greater  
311 proportion of males in this cohort (compared to other placebo-controlled trials in HS) may  
312 explain the slightly higher response rate in this cohort. Different patient factors are associated  
313 with clinical response in females as compared to males. In females, insulin resistance is also  
314 associated with clinical response suggesting a complex interplay between inflammation, sex  
315 hormones and metabolic comorbidities such as polycystic ovarian syndrome (PCOS).  
316 Additionally, responders were associated with increased numbers of baseline lesional IL23p19+  
317 and CD11c+ cells in dermal inflammatory infiltrates as well as upregulation of Th17  
318 inflammatory pathways. Data from this observational study suggests that sex hormones may be  
319 associated with IL-23p19 expressing CD11c+ cells in HS lesional tissue, which are associated  
320 with elevations in the Th17 immune axis and therefore clinical response to IL-23 antagonism.  
321  
322 This study was not designed to look at causation, and hence only associative conclusions can be  
323 drawn. It may be that serum testosterone and serum FSH are surrogate markers for other  
324 causative mechanisms which are currently unknown. What this study does provide is  
325 observational evidence that clinical response to IL-23 antagonism associates with alterations in  
326 serum sex hormones. Additionally, these hormone alterations are associated with Th17  
327 immune axis skewing, upregulation of *MAPK10* gene expression in lesional tissue and increases  
328 in CD11c+ cell populations in lesional tissue.

329  
330 Levels of sex hormones are influenced by age, the menstrual cycle, pregnancy and medication  
331 such as the contraceptive pill<sup>29,30</sup>. Whilst the influence of sex hormones on the activity of HS is  
332 well documented<sup>10</sup>, the link between sex hormones and inflammatory cytokines and  
333 chemokines in HS is not well understood. Monocyte populations are known to be altered in the  
334 setting of HS<sup>19,26,27</sup> with trends toward non-classical populations observed<sup>19,26,27</sup> but little data  
335 has observed differences in monocyte populations between men and women with HS.

336  
337 PCOS is known to alter the populations and activity of CD11c+ monocytes<sup>31</sup>, and sex hormones  
338 can alter monocyte differentiation with testosterone driving a non-classical monocyte  
339 differentiation and estrogens forming a classical differentiation program<sup>32-25</sup>. This is manifest by  
340 alterations in CD14 and CD16 expression, however this data has not been replicated in HS.  
341 Additionally, estrogens can depress the dendritic cell stimulation of T cells, and testosterone  
342 promote inflammatory activation of monocyte-derived dendritic cells<sup>32-35</sup>.

343  
344 Our presented results would be consistent with previous observations that sex hormones may  
345 impact the ratio of classical/intermediate/non-classical monocytes<sup>32-25</sup>. An overarching  
346 explanation for the observations in this study would be that elevated levels of testosterone in  
347 IL-23 clinical responders may result in preferential intermediate and non-classical monocyte  
348 polarization (via *MAPK10* and *CXCL1* gene expression<sup>32</sup>), manifesting in high levels of CD11c  
349 expression and Th17 immune polarization compared to IL-23 clinical non-responders.

350

351 An additional novel feature of this report is the utilization of the nCounter Nanostring gene  
352 expression system, which when used in other inflammatory dermatoses<sup>36</sup> has suggested higher  
353 sensitivity than traditional RNAseq (particularly with inflammatory cytokines such as IL-17  
354 isoforms). The similar upregulation of inflammatory targets in lesional, perilesional and non-  
355 lesional tissue when compared to other published datasets<sup>5,27,28</sup> partially validates the use of  
356 this gene expression method in HS.

357  
358

359 **Limitations:**

360 Limitations to this study include the small number of participants, the cohort nature of the  
361 study and the use of only baseline serum and tissue data as opposed to pre and post  
362 intervention sampling. The use of gene expression panel (nCounter) is reliant on a prior  
363 identified gene groups as opposed to assumption free RNAseq. However, the increased  
364 sensitivity of this technology promotes possible benefits from this over and above traditional  
365 RNA sequencing. The observations gained can only look into association not causation of sex  
366 hormones, CD11c+ populations and clinical response. All women included in this study were not  
367 on any form of contraceptive therapy. Hence the potential beneficial or detrimental role of  
368 exogenous hormones was not able to be assessed. Additionally, levels of tissue aromatase  
369 (which can convert androgens to estrogens) was not assessed. This may account for disparity  
370 between serum levels of sex hormones and their local action in tissue.

371 Future directions would include looking at pre and post interventional studies to potentiate  
372 response to IL-23 antagonisms (through the use of hormonal manipulation), the role of sex  
373 hormones in monocyte subsets in inflammatory skin disease, as well as exploring the effect of

374 the OCP other hormonal agents (such as Spironolactone) in concert with IL-23 antagonism in  
375 HS.

376

377

378 **Conclusions:**

379 Overall, individuals demonstrating a clinical response to IL-23 antagonism in HS exhibit elevated  
380 levels of total serum testosterone and elevated CD11c+ cell numbers in lesional tissue. Elevated  
381 expression of *IL17A*, *PLPP4* and *MAPK10* genes were observed in clinical responders suggesting  
382 a potential link between sex hormones and modulation of monocyte differentiation in HS  
383 tissue. These potential therapeutic biomarkers require validation in larger cohorts, and the  
384 influence of hormonal medications in potentiating or facilitating clinical response to IL-23  
385 antagonism may be an interesting future direction of translational research.

386

387

388

389

390

391

392

393

394

395



396

397

398

399

400 **References:**

- 401 1) Frew JW, Marzano AV, Wolk K, Join-Lambert O, Alavi A, Lowes MA, Piguet V. A  
402 Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A  
403 Critical Evaluation of Mechanistic and Clinical Relevance J Invest Dermatol 2021;  
404 141(2):216-324
- 405 2) Kimball AB, Okum MM, Williams DA, Gottlieb AB, Papp KA Zouboulis CC et al Two Phase  
406 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med 2016; 375:422-434
- 407 3) Schlapbach C, Hanni T, Yawalkar N, Hunger RE et al. Expression of the IL-23/Th17  
408 pathway in lesions of Hidradenitis Suppurativa. J Am Acad Dermatol 2011; 65(4):790-  
409 798
- 410 4) Navrazhina K, Frew JW, Krueger JG Interleukin 17C is elevated in lesional tissue of  
411 Hidradenitis Suppurativa. Br J Dermatol 2020;182(4):1045-1047
- 412 5) Witte Handel E, Wolk K, Tsaousi A, Irmer ML, Mossner R, Shomroni O, et al The IL-1  
413 Pathway is Hyperactive in Hidradenitis Suppurativa and Contributed to Skin Infiltration  
414 and Destruction. J Invest Dermatol 2019;139(6):1294-1305
- 415 6) Berman HS, Villa NM, Shi VY, Hsaio JL Guselkumab in the treatment of concomitant  
416 hidradenitis suppuratia, psoriasis and Crohn's disease. Dermatological Treatment 2021; ,  
417 32(2): 261-263

- 418 7) Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, Jemec GBE, Del Marmol V, Marzano  
419 AV, Nikolakis G, Sayed CJ, Tzellos T, Wolk K, Prens EP. Target molecules for future  
420 hidradenitis suppurativa treatment. *Exp Dermatol*. 2021 Jun;30 Suppl 1:8-17
- 421 8) Clinicaltrials.gov (NCT 03628924) A Study to Evaluate the Efficacy, Safety and  
422 Tolerability of Guselkumab for the Treatment of Participants with Moderate To Severe  
423 Hidradenitis Suppurativa (HS) (NOVA). Retrieved 28<sup>th</sup> Sept 2022 from  
424 <https://clinicaltrials.gov/ct2/show/NCT03628924>
- 425 9) Kok Y, Nicolopoulos J, Howard A, Varigos G, Kern J, Doliantis C. Tildrakizumab in the  
426 treatment of moderate-to-severe hidradenitis suppurativa. *Australas J Dermatol*  
427 2020;61(4):e488-e490
- 428 10) Kozera E, Lowes MA, Hsaio JL, Frew JW Clinical Considerations in the management of  
429 hidradenitis suppurativa in women. *Int J Womens Dermatol* 2021;7(5PartB):664-671
- 430 11) Moulton VR Sex Hormones in Acquired Immunity and Autoimmune Disease *Front*  
431 *Immunol* 2018; 02279
- 432 12) Riis PT, Ring HC, Themstrup L, Jemec GB. The role of androgens and estrogens in  
433 Hidradenitis Suppurativa – An Systematic Review. *Acta Dermatovenerologica Croatica*  
434 2016, 24(4):239-249
- 435 13) Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M et al IL23 Secreted by  
436 myeloid cells drives castration resistant prostate cancer. *Nature* 2018;559(7714):363-  
437 369

- 438 14) Silva e Souza CL, Barbosa CD, Coelho HILN, Santos-Junior M, Barbosa EN, Queiroz EC,  
439 Effects of 17B Estradiol on Monocyte/Macrophage Response to Staphylococcus aureus:  
440 An in vitro study. Front Cell Infect Microbiol 2021; Fcimb.2021.701391
- 441 15) Segerer SE, Muller N, van den Brandt J, Kapp M, Dietl J, Reichardt HM et al. Impact of  
442 female sex hormones on the maturation and function of human dendritic cells. Am J  
443 Reprod Immunol 2009 62(3):165-73
- 444 16) Vossen ARJV, van der Zee, Prens EP Hidradenitis Suppurativa: A Systematic review  
445 Integrating Inflammatory pathways into a Cohesive Pathogenic Model. Front Immunol  
446 2018;9:2965
- 447 17) Wolk K, Join-Lambert O, Sabat R Aetiology and pathogenesis of Hidradenitis  
448 Suppurativa. Br J Dermatol 2020; 183(6):999-1010
- 449 18) Frew JW, Hawkes JE, Krueger JG A Systematic Review and Critical Evaluation of  
450 Immunohistochemical Associations in Hidradenitis Suppurativa. F1000Res 2018;7:1923
- 451 19) Kanni T, Tzanetakou V, Savva A, Kersten B, Pistiki A, van de Veerdonk F et al  
452 Compartmentalized cytokine responses in Hidradenitis Suppurativa. PLoS One  
453 2015;10(6):e0130522
- 454 20) Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GBE Hidradenitis  
455 Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification  
456 and Disease Evaluation. Dermatology 2015;231(2):184-190
- 457 21) Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J et al Efficacy and Safety  
458 of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa. JAMA Dermatol  
459 2021;157(11):1279-1288

- 460 22) Frew JW, Navrazhina K, Byrd AS, Garg A, Ingram JR, et al. Defining lesional, perilesional  
461 and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical  
462 trials and translational research studies. Br J Dermatol 2019;181(6):13391-341
- 463 23) Goytain A, Ng T Nanostring nCounter Technology: High-Throughput RNA Validation  
464 Methods Mol Biol 2020; 2079:125-139
- 465 24) Crowe AR, Yue W Semi-quantitative Determination of Protein Expression using  
466 Immunohistochemistry staining and Analysis: An Integrated Protocol. Bio Protoc.  
467 2019;9(24):e3465
- 468 25) Bhattacharya A, Hamilton AM, Furberg H, Pietzak E, Purdue MP, Troester MA et al An  
469 approach for normalization and quality control for Nanostring RNA expression data. Brief  
470 Bioinform 2021;22(3):bbaa163
- 471 26) Gudjonsson JE, Tsoi LC, Ma F, Billi AC, van Straalen KR, Vossen ARJV et al Contribution of  
472 plasma cells and B cells to hidradenitis suppurativa pathogenesis. JCI Insight  
473 2020;5(19):e139930
- 474 27) Lowe MM, Naik HB, Clancy S, Pauli M, Smith KM, Bi Y, et al Immunopathogenesis of  
475 hidradenitis suppurativa and response to anti-TNF- $\alpha$  therapy. JCI insight  
476 2020;5(19):e139932
- 477 28) Navrazhina K, Frew JW, Grand D, Williams SC, Hur H, Gonzalez J et al Interleukin-17RA  
478 blockade by Brodalumab decreases inflammatory pathways in hidradenitis suppurativa  
479 skin and serum. Br J Dermatol 2022;187(2):223-233

- 480 29) Lee SJ, Lenton EA, Sexton L, Cooke ID The effect of age on the cyclical patterns of plasma  
481 LH, FSH oestradiol and progesterone in women with regular menstrual cycles. Hum  
482 Reprod 1988;3(7): 851-855
- 483 30) Raju GAR, Chavan R, Deenadayal M, Gunasheela D, Gutgutia R, Haripriya G et al  
484 Luteinizing hormone and follicle stimulating hormone synergy: A review of role in  
485 controlled ovarian hyper-stimulation. J Hum Reprod Sci 2013;6(4):227-34
- 486 31) Huang ZH, Manickam B, Ryvkin V, Zhou J, Fantuzzi G, Mazzone T, Sam S. PCOS is  
487 associated with increased CD11c Expression and Crown like structures in Adipose tissue  
488 and increased central abdominal fat deposits independent of obesity. J Clin Endocrin  
489 Metab 2013;98(1):E17-E24
- 490 32) Sellau J, Groneberg M, Fehling H et al Androgens predispose males to monocyte  
491 mediated immunopathology by inducing the expression of leucocyte recruitment factor  
492 CXCL1 Nat Commun 11, 3459 2020
- 493 33) Becerra-Diaz M, Song M, Heller N Androgen and Androgen receptors as regulators of  
494 monocyte and macrophage biology in the healthy and diseased lung Front Immunol  
495 2020.....
- 496 34) Pelekanaou V, Kampa M, Kiagiadaki F, Deli A, Theodoropoulos P, Agogiannis G et al  
497 Estrogen anti-inflammatory activity on human monocytes is mediated through cross-talk  
498 between estrogen receptor Era36 and GPR30/GPER1 J Leucoc Biol 2016; 99(2):333-347
- 499 35) Kramer PR, Winger V, Kramer SF 17-B Estradiol utilizes the estrogen receptor to regulate  
500 CD16 expression in monocytes. Mol Cell Endocrinol 2007;279(1-2):16-25

501 36) Krueger JG Wharton KA, Schlitt T, IL-17A inhibition by secukinumab induces early clinical  
502 histopathologic, and molecular resolution of psoriasis. J Allerg Clin Immunol 2019;  
503 144(3): 750-763

504

505 **Figures and Tables:**

506

507 Table 1: Table of summary demographic and disease data of participants in this cohort study.

508

509 Figure 2: Comparison of Baseline Serum Testosterone and Serum FSH levels in Responders and  
510 Non-Responders (at week 16) to Risankizumab therapy for Hidradenitis Suppurativa as well as  
511 receiver operating curve for testosterone and HiSCR50.

512

513 Figure 3: Baseline Multiplex gene expression (Nanostring) data for baseline tissue biopsies in 26  
514 participants, stratified by lesional, perilesional and non lesional tissue.

515

516 Figure 4: Log fold change in gene expression of select genes in responders versus non-  
517 responders in Hidradenitis Suppurativa. Statistically significant elevation in gene expression was  
518 seen in T cell, macrophage monocyte and dendritic cell genes compared to non-responders.

519 This included IL-17A, CXCR1, TRAT1 and LTA. Principal component analysis demonstrating  
520 discrete clustering of Responders and Non-Responders based on gene expression data.

521

522 Figure 5: Immunohistochemical staining for IL-23p19, CD11c, IL-17A and IL-17F are associated  
523 with clinical response to Risankizumab therapy in Hidradenitis Suppurativa.

524

525

526

527 **Supplementary Figures:**

528

529 Supp Figure 1: Representative clinical photographs of response to Risankizumab therapy at  
530 Week 16

531

532 Supp Figure 2: Comparison of FSH and Total Testosterone between Responders and Non  
533 responders stratified by HiSCR75 and HiSCR90.

534

535 Supp Figure 3: Comparison of Sex Hormone Binding Globulin (SHBG); Luteinizing Hormone (LH),  
536 and Body Mass Index (BMI) between Responders and Non-Responders stratified by HISC50

537

538 Supplementary Figure 4: Comparison of Age, Sex Hormone Binding Globulin (SHBG); Body Mass  
539 Index (BMI), Luteinizing Hormone (LH), and free testosterone between Responders and Non-  
540 Responders stratified by HISC75

541

542 Supplementary Figure 5: Comparison of Sex Hormone Binding Globulin (SHBG); Age, free  
543 testosterone, Luteinizing Hormone (LH), Body Mass Index (BMI), and between Responders and  
544 Non-Responders stratified by HISC90

545  
546 Supplementary Figure 6: Principal Component Analysis demonstrating clustering of lesional and  
547 perilesional tissue samples distinct from non lesional samples with highlighted associated  
548 genes. Log2Fold change of genes in lesional, perilesional and non-lesional tissue compared to  
549 site-matched healthy controls.

550  
551 Supplementary Figure 7: Heatmap with hierarchical clustering demonstrating discrete  
552 clustering of Responders and Non-Responders to Risankizumab in Hidradenitis Suppurativa.

553  
554 Supplementary Figure 8: Representative immunohistochemistry for CD11c and IL23p19 in  
555 responders and non responders to Risankizumab in Hidradenitis Suppurativa. Additionally,  
556 correlation between Serum FSH and Serum Testosterone with CD11c+ IHC score.

557

558

559 **Supplementary Tables:**

560 Supp Table 1: Inclusion, Exclusion Criteria

561 Supp Table 2: Table of Individual Patient Characteristics of participants

562 Supp Table 3: nCounter Human Fibrosis V2.0 Gene List

563 Supp Table 4: Data from the NOVA Trial adapted from NCT03628924



564 Supp Table 5: Reactome Pathway Analysis of Responders to Risankizumab Therapy

565 Supp Table 6: Logistic Regression analyses for HiSCR50/ HiSCR75 and HiSCR90

566

567


568

569


| Variable                        | Total (n=26)   | (HiSCR50)   |  | P-Value |
|---------------------------------|--|---|--|---------|
|                                 |  | Responders<br>(18/26, 69.2%)                            | Non-Responders<br>(8/26, 30.8%)                  |         |
| Gender n (%)                    | Male: 15 (57.7%)<br>Female: 11 (42.3%)               | Male 14/18 (77.8%)<br>Female 4/18 (22.2%)               | Male: 1/8 (12.5%)<br>Female: 7/8 (87.5%)         | P<0.01  |
| Age (Median)                    | Median=31.5  | Median= 31  | Median=40  | P=0.08  |
| BMI (Median)                    | Median=28  | Median=28   | Median= 36.5                                     | P=0.11  |
| Insulin Resistance n, (%)       | 4/26 (15.4%)   | 4/18 (22.2%)  | 0/8 (0%)   | P<0.001 |
| Hurley Stage (n,%)              | Hurley 2:<br>13/26 (50%)<br>Hurley 3:<br>13/26 (50%) | Hurley 2:<br>7/18 (38.9%)<br>Hurley 3:<br>11/18 (61.1%) | Hurley 2:<br>6/8 (75%)<br>Hurley 3:<br>2/8 (25%) | P=0.06  |
| Baseline IHS4 Score (Median)    | 42   | 40  | 41   | P=0.87  |
| Median Serum Total Testosterone | 9.7nmol/L  | 20.3 nmol/L   | 1.0 nmol/L                                       | P<0.001 |
| Serum FSH                       | 6.2 mIU/mL   | 3.2 mIU/mL  | 10 mIU/mL  | P<0.001 |
| Serum LH                        | 5.45 IU/L  | 4.5 IU/L  | 16.5 IU/L  | P=0.01  |
| Serum CRP                       | 12.3 mg/L  | 13.0 mg/L   | 11.2 mg/L  | P=0.36  |




IL6ST  
CCR2  
IL1B  
TLR4  
IL13  
MARCO  
TRAT1  
C3AR1  
S100A12  
TNFRSF17  
CXCL8  
PLPP4  
MAPK9  
SYK  
CXCL11  
MMP8  
TLR6  
MS4A4A  
MYD88  
ADAM17  
IGF1  
S100A4  
CXCR4  
NUMB  
CSF1R  
IRAK3  
CD209  
TNF  
GZMB  
MMP13  
CD244  
FCRL2  
IFNG  
CXCR6  
IRF8  
CCL13  
CD163  
IRS1  
CD86  
TLR2  
CXCR1  
MYL2  
MAPK10  
ICOS  
OCLN  
CXCL10  
PPARG  
MFAP3  
NOTCH1  
ECD14  
CD68  
CKAP4  
HLA-E  
COL14A1  
GATA3  
HLA-DQA1  
KDM5D  
CTNND1  
RELA  
TRAF6  
TPSAB1/B2  
LTB  
BCL2  
CXCL2  
MMP9  
FOXP3  
IL6  
VAV1  
C5  
STAT5A  
CEACAM3  
MMP2  
MMP7  
VIM  
MMP14  
NOTCH3  
MTOR  
CCL2  
PSEN2  
JAK2



Lesional



Perilesional



Non-Lesional

medRxiv preprint doi: <https://doi.org/10.1101/2023.02.22.23286201>; this version posted February 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

